Abstract:

Objective To investigate the effect of SIRT1 gene polymorphism on the clinical efficacy of liraglutide combined with metformin in type 2 diabetes patients with poor glycemic control. Methods 216 type 2 diabetes patients with poor glycemic control were included. Patients were treated with liraglutide combined with metformin. After 26 weeks treatment，the clinical efficacy was evaluated，and the relationship between SIRT1 gene polymorphism and efficacy was analyzed. Results After 26 weeks of treatment with lialulutide combined with metformin，the indexes of HbA1c，FPG，2H PG and BMI of 216 patients were significantly decreased，and the differences were statistically significant compared with those before treatment（P < 0.05）. The indexes of HbA1c， FPG，BMI and 2h PG in TC/CC patients decreased more significantly than those in TT patients，and the differences were statistically significant（P < 0.05）. The polymorphism analysis of SIRT1 gene showed that the genotype distri⁃ bution frequency of Rs12778366 was in line with hardy Weinberg equilibrium. In addition，the STIR1 mRNA expression analysis of 145 patients showed that the mRNA expression level of TT patients was also significantly lower than that of TC/CC patients（P < 0.001）. Conclusions Lilarutide combined with metformin is safe and effective in patients with type 2 diabetes with poor glycemic control，and patients with C allele are more effective. Rs12778366 of SIRT1 gene may affect the clinical efficacy of lylalutide combined with metformin by affecting the mRNA expres⁃ sion of SIRT1 gene.

Key words: